Literature DB >> 19837907

Interspecies scaling of therapeutic monoclonal antibodies: initial look.

Jie Ling1, Honghui Zhou, Qun Jiao, Hugh M Davis.   

Abstract

The authors evaluated interspecies scaling for the prediction of human clearance of 18 therapeutic monoclonal antibodies (mAbs). Human and monkey/chimpanzee data of 14 mAbs were classified based on the targeted antigens (soluble or membrane bound). Simple allometry and/or a time-invariant method (elementary Dedrick plot) were performed. Results indicate that human clearance might be accurately predicted from monkey data for mAbs targeting soluble receptors or membrane-bound receptors with limited tissue distribution using simplified allometry. The optimal exponents were estimated to be 0.85 or 0.90. If nonlinearity is anticipated at the human efficacious dose, pharmacokinetic parameters obtained at high doses in animals might not be sufficient for full pharmacokinetic characterization and prediction. Using prespecified criteria, including predicted human clearance (< or = or > 10 mL/d/kg), simplified allometric scaling might be helpful in predicting the effect of receptor-mediated clearance for mAbs targeting membrane-bound antigens. Furthermore, simplified allometry and an elementary Dedrick plot provide similar results in predicted clearance. Given the significant advantages offered by simplified allometry, it should be used when data are available from only 1 species. When reasonable data from > or =3 species are available, traditional allometry should be explored. Overall, clearance prediction is useful for human dose prediction in drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837907     DOI: 10.1177/0091270009337134

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  48 in total

Review 1.  Prediction of exposure-response relationships to support first-in-human study design.

Authors:  John P Gibbs
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

Review 2.  Pharmacokinetic considerations for antibody drug conjugates.

Authors:  Kedan Lin; Jay Tibbitts
Journal:  Pharm Res       Date:  2012-06-28       Impact factor: 4.200

3.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.

Authors:  Jie Zhao; Yanguang Cao; William J Jusko
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

4.  A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Authors:  Patrick Poulin
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

5.  Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

Authors:  Aman P Singh; Wojciech Krzyzanski; Steven W Martin; Gregory Weber; Alison Betts; Alaa Ahmad; Anson Abraham; Anup Zutshi; John Lin; Pratap Singh
Journal:  AAPS J       Date:  2014-12-03       Impact factor: 4.009

6.  A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide.

Authors:  Elliot Offman; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-04       Impact factor: 2.745

Review 7.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

Authors:  Miroslav Dostalek; Thomayant Prueksaritanont; Robert F Kelley
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

Review 8.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 9.  Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Authors:  Y Zhang; S Doshi; M Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-05-26       Impact factor: 4.335

10.  Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.

Authors:  Yulia Vugmeyster; Cynthia Rohde; Mylene Perreault; Ruth E Gimeno; Pratap Singh
Journal:  MAbs       Date:  2013-03-25       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.